Full-year revenue growth 10-15%
Management expects overall top-line growth of 10-15% for FY26, excluding one-off items.
3BBLACKBIODX / guidance tracker
Keep management guidance in view.
3B Blackbio DX · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Export growth 15-20% for FY26
Exports are expected to grow 15-20% in FY26, driven by UK subsidiary and new registrations.
Chorus EBITDA positive at 2-4% next year
Chorus is targeted to become EBITDA positive at 2-4% of revenue in the next fiscal year.
Sample-to-answer machine launch next quarter
A new sample-to-answer system (OEM) is expected to be launched in the next quarter, targeting infection and oncology segments.